

Title (en)
ORAL LIQUID COMPOSITIONS OF GUANFACINE

Title (de)
ORALE FLÜSSIGE ZUSAMMENSETZUNGEN VON GUANFACIN

Title (fr)
COMPOSITIONS ORALES LIQUIDES DE GUANFACINE

Publication
EP 3288549 A4 20200115 (EN)

Application
EP 16789380 A 20160502

Priority
• IB 2015053209 W 20150501
• US 201615133826 A 20160420
• IB 2016052485 W 20160502

Abstract (en)
[origin: WO2016178131A1] The present invention relates to oral liquid compositions of guanfacine. The liquid compositions can be immediate release or extended release compositions. The compositions comprise guanfacine in a concentration from about 0.1 mg/mL, to about 12.0 mg/mL of the composition. The liquid compositions can be in the form of ready-to use liquid compositions or reconstituted liquid compositions. It further relates to processes for the preparation of said oral liquid compositions.

IPC 8 full level
A61K 9/10 (2006.01); **A61K 9/00** (2006.01); **A61K 9/14** (2006.01); **A61K 9/50** (2006.01); **A61K 31/165** (2006.01); **A61K 47/12** (2006.01)

CPC (source: EP US)
A61J 1/1418 (2015.05 - EP US); **A61J 1/18** (2013.01 - EP US); **A61J 1/2006** (2015.05 - EP US); **A61J 1/2027** (2015.05 - EP US); **A61J 1/2093** (2013.01 - EP US); **A61K 9/0095** (2013.01 - EP US); **A61K 9/10** (2013.01 - EP US); **A61K 9/145** (2013.01 - EP); **A61K 9/5015** (2013.01 - US); **A61K 9/5042** (2013.01 - EP US); **A61K 9/5047** (2013.01 - EP); **A61K 9/5084** (2013.01 - EP); **A61K 31/155** (2013.01 - EP US); **A61K 31/165** (2013.01 - EP); **A61K 31/43** (2013.01 - EP); **A61K 31/4439** (2013.01 - EP); **A61K 31/522** (2013.01 - EP); **A61K 47/12** (2013.01 - EP); **A61K 47/14** (2013.01 - US); **A61K 47/26** (2013.01 - US); **A61K 47/36** (2013.01 - US); **A61K 47/38** (2013.01 - US); **B65D 51/2835** (2013.01 - EP); **B65D 81/3211** (2013.01 - EP); **A61K 9/5089** (2013.01 - EP); **B65D 2401/25** (2020.05 - EP); **B65D 2401/50** (2020.05 - EP)

Citation (search report)
• [XP] WO 2015166473 A1 20151105 - SUN PHARMACEUTICAL IND LTD [IN]
• [X] US 2006193877 A1 20060831 - TENGLER MARK [US], et al
• [X] EP 2796133 A1 20141029 - SALMON PHARMA GMBH [CH]
• [X] US 5854290 A 19981229 - ARNSTEN AMY F T [US], et al
• [A] US 2013149383 A1 20130613 - BERKLAND CORY [US], et al
• [A] US 2004018233 A1 20040129 - DAVIS ROBERT D [US], et al
• [A] US 2003158261 A1 20030821 - BURNSIDE BETH A [US], et al
• [A] CONNOR D F ET AL: "Guanfacine extended release in the treatment of attention deficit hyperactive disorder in children and adolescents", DRUGS OF TODAY, PROUS SCIENCE, ES, vol. 46, no. 5, 1 May 2010 (2010-05-01), pages 299 - 314, XP002703180, ISSN: 1699-3993, DOI: 10.1358/DOT.2010.46.5.1450095
• See references of WO 2016178131A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2016178131 A1 20161110; EP 3288549 A1 20180307; EP 3288549 A4 20200115

DOCDB simple family (application)
IB 2016052485 W 20160502; EP 16789380 A 20160502